CADTH | Search

Current Filters

Showing 1 - 10 results of 3551

Emtricitabine/tenofovir disoproxil fumarate (Truvada) (Last Updated: Feb 4, 2016)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Truvada
Manufacturer:
Gilead Sciences Canada Inc.
Submission Type:
Initial
Indications:

HIV-1 infection, pre-exposure prophylaxis

Tesamorelin (Egrifta) (Last Updated: Oct 10, 2018)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Egrifta
Manufacturer:
Theratechnologies Inc.
Submission Type:
Initial
Indications:

Lipodystrophy, HIV-infected patients

Canagliflozin and metformin hydrochloride (Invokamet) (Last Updated: Oct 10, 2018)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Invokamet
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Diabetes mellitus, type 2

Apremilast (Otezla) (Last Updated: Jan 29, 2016)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Otezla
Manufacturer:
Celgene
Submission Type:
Resubmission
Indications:

Psoriasis, moderate to severe plaque

Opdivo for Metastatic Renal Cell Carcinoma – Details (Opdivo) (Last Updated: Sep 19, 2016)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Opdivo
Manufacturer:
Bristol Myers-Squibb Canada
Submission Type:
Initial

Secukinumab (Cosentyx) (Last Updated: Jan 21, 2016)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Cosentyx
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Arthritis, psoriatic

Secukinumab (Cosentyx) (Last Updated: Jan 21, 2016)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Cosentyx
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Ankylosing spondylitis

Lynparza (olaparib) (Lynparza) (Last Updated: Mar 9, 2020)

Project Line:
Reimbursement Review
Project Status:
Not filed
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Lynparza
Manufacturer:
AstraZeneca Canada
Submission Type:
Non-Submission

Acalabrutinib (Calquence) for chronic lymphocytic leukemia - Details (Calquence) (Last Updated: Jul 27, 2022)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Submission Type Indications

Brand Name:
Calquence
Manufacturer:
AstraZeneca Canada Inc
Submission Type:
Initial
Submission Type:
Initial
Indications:

​As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy

Download results as CSV